Patents by Inventor Chris Lock

Chris Lock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12152038
    Abstract: Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein Q1, Q2, Q3, R2a, R2b, R3 and X are as defined herein.
    Type: Grant
    Filed: March 5, 2021
    Date of Patent: November 26, 2024
    Assignee: Neumora Therapeutics, Inc.
    Inventors: Robert M. Jones, Mariangela Urbano, Gary Brandt, Mark Chambers, David Hardick, Chris Knight, Jason Tierney, Chris Lock
  • Publication number: 20240199624
    Abstract: The present disclosure relates generally to small molecule inhibitors of MutS? protein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, methods of making and intermediates thereof, and methods of using thereof.
    Type: Application
    Filed: November 28, 2023
    Publication date: June 20, 2024
    Inventors: Tasir Haque, Michel Maillard, Gareth Brace, George Ballantyne, Elizabeth Frush, Kim Hirst, Katherine Jones, Emanuela Gancia, Chris Lock, Cole Clissold
  • Publication number: 20210317126
    Abstract: Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein Q1, Q2, Q3, R2a, R2b, R3 and X are as defined herein.
    Type: Application
    Filed: March 5, 2021
    Publication date: October 14, 2021
    Inventors: Robert M. Jones, Mariangela Urbano, Gary Brandt, Mark Chambers, David Hardick, Chris Knight, Jason Tierney, Chris Lock
  • Patent number: 10538530
    Abstract: Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein Q1, Q2, Q3, R2a, R2b, R3 and X are as defined herein.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: January 21, 2020
    Assignee: BlackThorn Therapeutics, Inc.
    Inventors: Robert M. Jones, Mariangela Urbano, Gary Brandt, Mark Chambers, David Hardick, Chris Knight, Jason Tierney, Chris Lock
  • Publication number: 20190169202
    Abstract: Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein Q1, Q2, Q3, R2a, R2b, R3 and X are as defined herein.
    Type: Application
    Filed: September 5, 2018
    Publication date: June 6, 2019
    Inventors: Robert M. Jones, Mariangela Urbano, Gary Brandt, Mark Chambers, David Hardick, Chris Knight, Jason Tierney, Chris Lock
  • Patent number: D744983
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: December 8, 2015
    Assignee: Allen & Heath Limited
    Inventors: Glenn Rogers, Robin Clark, Mike Williamson, Carey Davies, James Wrigley, Alex Money, John Danning, David Price, Ian McBurney, Simon Trethewey, David Cook, David Biggs, Niall Dunican, Chris Lock